The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape

Journal of Pathology

Volumn 221, Issue 3, 2010, Pages 248-263

  Aldinucci, Donatella ^a   Gloghini, Annunziata ^b   Pinto, Antonio ^c   De Filippi, Rosaria ^c,d   Carbone, Antonino ^a,b  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Classical Hodgkin's lymphoma; Immune escape; Therapeutic targets; Tumour microenvironment

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; BLEOMYCIN; CHEMOKINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IBRITUMOMAB TIUXETAN; L16 ANTIBODY; L19 ANTIBODY I 131; LENALIDOMIDE; PENTOSTATIN; PREDNISONE; PROCARBAZINE; RITUXIMAB; TOSITUMOMAB; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; B LYMPHOCYTE; CELL INTERACTION; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLASSICAL HODGKIN LYMPHOMA; DRUG TARGETING; HODGKIN DISEASE; HUMAN; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; REED STERNBERG CELL; REVIEW; T LYMPHOCYTE; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

ANTINEOPLASTIC AGENTS; CELL COMMUNICATION; HODGKIN DISEASE; HUMANS; IMMUNOPHENOTYPING; PROGNOSIS; REED-STERNBERG CELLS; TUMOR ESCAPE; TUMOR MARKERS, BIOLOGICAL;

EID: 77953534075     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2711     Document Type: Review

References (137)

1. Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio F. The microenvironment in mature B cell malignancies: a target for new treatment strategies. Blood 2009; 114: 3367-3375.
2. Chantrain CF, Feron O, Marbaix E, Declerck YA. Bone marrow microenvironment and tumour progression. Cancer Microenviron 2008; 1: 23-35.
3. Küppers R. The biology of Hodgkin's lymphoma. Nat Rev Cancer 2009; 9: 15-27.
4. Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood 2002; 99: 4283-4297. (Pubitemid 34627193)
5. Schreck S, Friebel D, Buettner M, Distel L, Grabenbauer G, Young LS, et al . Prognostic impact of tumour-infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma. Hematol Oncol 2009; 27: 31-39.
6. Juszczynski P, Ouyang J, Monti S, Rodig SJ, Takeyama K, Abramson J, et al . The AP1-dependent secretion of galectin- 1 by Reed-Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc Natl Acad Sci USA 2007; 104: 13134-13139. (Pubitemid 351737605)
7. Lamprecht B, Kreher S, Anagnostopoulos I, Jöhrens K, Monteleone G, Jundt F, et al . Aberrant expression of the Th2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts Treg cells via regulation of MIP-3α. Blood 2008; 112: 3339-3347.
8. Pinto A, Aldinucci D, Gloghini A, Zagonel V, Degan M, Perin V, et al . The role of eosinophils in the pathobiology of Hodgkin's disease. Ann Oncol 1997; 8: 89-96.
9. Carbone A, Gloghini A, Gattei V, Aldinucci D, Degan M, De Paoli P, et al . Expression of functional CD40 antigen on Reed-Sternberg cells and Hodgkin's disease cell lines. Blood 1995; 85: 780-789.
10. Aldinucci D, Lorenzon D, Olivo K, Rapana B, Gattei V. Interactions between tissue fibroblasts in lymph nodes and Hodgkin/Reed-Sternberg cells. Leuk Lymphoma 2004; 45: 1731-1739. (Pubitemid 38997138)
11. Aldinucci D, Olivo K, Lorenzon D, Poletto D, Gloghini A, Carbone A, et al . The role of interleukin-3 in classical Hodgkin's disease. Leuk Lymphoma 2005; 46: 303-311. (Pubitemid 40220389)
12. Aldinucci D, Lorenzon D, Cattaruzza L, Pinto A, Gloghini A, Carbone A, et al . Expression of CCR5 receptors on Reed-Sternberg cells and Hodgkin lymphoma cell lines: involvement of CCL5/RANTES in tumour cell growth and microenvironmental interactions. Int J Cancer 2008; 122: 769-776.
13. Cattaruzza L, Gloghini A, Olivo K, Di Francia R, Lorenzon D, De Filippi R, et al . Functional coexpression of Interleukin (IL)-7 and its receptor (IL-7R) on Hodgkin and Reed-Sternberg cells: involvement of IL-7 in tumour cell growth and microenvironmental interactions of Hodgkin's lymphoma. Int J Cancer 2009; 125: 1092-1101.
14. Rautert R, Schinköthe T, Franklin J, Weihrauch M, Boll B, Pogge E, et al . Elevated pretreatment interleukin-10 serum level is an international prognostic score (IPS)-independent risk factor for early treatment failure in advanced stage Hodgkin lymphoma. Leuk Lymphoma 2008; 49: 2091-2098.
15. Niens M, Visser L, Nolte IM, van der Steege G, Diepstra A, Cordano P, et al . Serum chemokine levels in Hodgkin lymphoma patients: highly increased levels of CCL17 and CCL22. Br J Haematol 2008; 140: 527-236. (Pubitemid 351230079)
16. Evens AM, Hutchings M, Diehl V. Treatment of Hodgkin lymphoma: the past, present, and future. Nat Clin Pract Oncol 2008; 5: 543-556.
17. Koenecke C, Ukena SN, Ganser A, Franzke A. Regulatory T cells as therapeutic target in Hodgkin's lymphoma. Expert Opin Ther Targets 2008; 12: 769-782. (Pubitemid 351877305)
18. Buglio D, Georgakis GV, Hanabuchi S, Arima K, Khaskhely NM, Liu YJ, et al . Vorinostat inhibits STAT6- mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. Blood 2008; 112: 1424-1433.
19. Stein H, Delsol G, Pileri SA, Weiss LM, Poppema S, Jaffe ES. Classical Hodgkin lymphoma, introduction. In WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn, Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. (eds). IARC: Lyon, 2008; 326-329.
20. Falini B, Fizzotti M, Pucciarini A, Bigerna B, Marafioti T, Gambacorta M, et al . A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood 2000; 95: 2084-2092.
21. Carbone A, Gloghini A, Aldinucci D, Gattei V, Dalla-Favera R, Gaidano G. Expression pattern of MUM1/IRF4 in the spectrum of pathology of Hodgkin's disease. Br J Haematol 2002; 117: 366-372. (Pubitemid 34451152)
22. Carbone A, Gloghini A, Gruss HJ, Pinto A. CD40 ligand is constitutively expressed in a subset of T cell lymphomas and on the microenvironmental reactive T cells of follicular lymphomas and Hodgkin's disease. Am JPathol 1995; 147: 912-922.
23. Marshall NA, Christie LE, Munro LR, Culligan DJ, Johnston PW, Barker RN, et al . Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 2004; 103: 1755-1762.
24. Yamamoto R, Nishikori M, Kitawaki T, Sakai T, Hishizawa M, Tashima M, et al . PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood 2008; 111: 3220-3224.
25. Dorfman DM, Brown JA, Shahsafaei A, Freeman GJ. Programmed death-1 (PD-1) is a marker of germinal centerassociated T cells and angioimmunoblastic T-cell lymphoma. Am J Surg Pathol 2006; 30: 802-810. (Pubitemid 44264969)
26. Riley JL, June CH. The CD28 family: A T-cell rheostat for therapeutic control of T-cell activation. Blood 2005; 105: 13-21.
27. Blank C, Gajewski TF, Mackensen A. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother 2005; 54: 307-314. (Pubitemid 40238924)
28. Hirano F, Kaneko K, Tamura H, Dong H, Wang S, Ichikawa M, et al . Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 2005; 65: 1089-1096.
29. Iwai Y, Terawaki S, Honjo T. PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int Immunol 2005; 17: 133-144. (Pubitemid 40246578)
30. Shimabukuro-Vornhagen A, Haverkamp H, Engert A, Balleisen L, Majunke P, Heil G, et al . Lymphocyte-rich classical Hodgkin's lymphoma: clinical presentation and treatment outcome in 100 patients treated within German Hodgkin's Study Group trials. J Clin Oncol 2005; 23: 5739-5745.
31. Bräuninger A, Wacker HH, Rajewsky K, Küppers R, Hansmann ML. Typing the histogenetic origin of the tumor cells of lymphocyte-rich classical Hodgkin's lymphoma in relation to tumor cells of classical and lymphocyte-predominance Hodgkin's lymphoma. Cancer Res 2003; 63: 1644-1651. (Pubitemid 36373657)
32. Nam-Cha SH, Montes-Moreno S, Salcedo MT, Sanjuan J, Garcia JF, Piris MA. Lymphocyte-rich classical Hodgkin's lymphoma: distinctive tumor and microenvironment markers. Mod Pathol 2009; 22: 1006-1015.
33. Bechtel D, Kurth J, Unkel C, Kuppers R. Transformation of BCR-deficient germinal-center B cells by EBV supports a major role of the virus in the pathogenesis of Hodgkin and posttransplantation lymphomas. Blood 2005; 106: 4345-4350. (Pubitemid 41775946)
34. Chaganti S, Bell AI, Pastor NB, Milner AE, Drayson M, Gordon J, et al . Epstein-Barr virus infection in vitro can rescue germinal center B cells with inactivated immunoglobulin genes. Blood 2005; 106: 4249-4252. (Pubitemid 41775933)
35. Mancao C, Altmann M, Jungnickel B, Hammerschmidt W. Rescue of 'crippled' germinal center B cells from apoptosis by Epstein-Barr virus. Blood 2005; 106: 4339-4344.
36. Marshall NA, Culligan DJ, Tighe J, Johnston PW, Barker RN, Vickers MA. The relationships between Epstein-Barr virus latent membrane protein 1 and regulatory T cells in Hodgkin's lymphoma. Exp Hematol 2007; 35: 596-604. (Pubitemid 46427965)
37. Maggio E, van den Berg A, Diepstra A, Kluiver J, Visser L, Poppema S. Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues. Ann Oncol 2002; 13: 52-56. (Pubitemid 34567402)
38. Uchihara JN, Krensky AM, Matsuda T, Kawakami H, Okudaira T, Masuda M, et al . Transactivation of the CCL5/RANTES gene by Epstein-Barr virus latent membrane protein 1. Int J Cancer 2005; 114: 747-755. (Pubitemid 40344436)
39. Baumforth KR, Birgersdotter A, Reynolds GM, Wei W, Kapatai G, Flavell JR, et al . Expression of the Epstein-Barr virus-encoded Epstein-Barr virus nuclear antigen 1 in Hodgkin's lymphoma cells mediates up-regulation of CCL20 and the migration of regulatory T cells. Am J Pathol 2008; 173: 195-204.
40. Buri C, Korner M, Scharli P, Cefai D, Uguccioni M, Mueller C, et al . CC chemokines and the receptors CCR3 and CCR5 are differentially expressed in the non-neoplastic leukocytic infiltrates of Hodgkin disease. Blood 2001; 97: 1543-1548.
41. Fischer M, Juremalm M, Olsson N, Backlin C, Sundstrom C, Nilsson K, et al . Expression of CCL5/RANTES by Hodgkin and Reed-Sternberg cells and its possible role in the recruitment of mast cells into lymphomatous tissue. Int J Cancer 2003; 107: 197-201.
42. Ohshima K, Karube K, Hamasaki M, Tutiya T, Yamaguchi T, Suefuji H, et al . Differential chemokine, chemokine receptor and cytokine expression in Epstein-Barr virus-associated lymphoproliferative diseases. Leuk Lymphoma 2003; 44: 1367-1378.
43. Khan G. Epstein-Barr virus, cytokines, and inflammation: a cocktail for the pathogenesis of Hodgkin's lymphoma? Exp Hematol 2006; 34: 399-406.
44. Re D, Thomas RK, Behringer K, Diehl V. From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential. Blood 2005; 105: 4553-4560.
45. Aldinucci D, Poletto D, Nanni P, Degan M, Gloghini A, Di Francia R, et al . Hodgkin and Reed-Sternberg cells express functional c-kit receptors and interact with primary fibroblasts from Hodgkin's disease-involved lymph nodes through soluble and membrane-bound stem cell factor. Br J Haematol 2002; 118: 1055-1064.
46. Aldinucci D, Poletto D, Gloghini A, Nanni P, Degan M, Perin T, et al . Expression of functional interleukin-3 receptors on Hodgkin and Reed-Sternberg cells. Am J Pathol 2002; 160: 585-596.
47. Jundt F, Anagnostopoulos I, Bommert K, Emmerich F, Muller G, Foss HD, et al . Hodgkin/Reed-Sternberg cells induce fibroblasts to secrete eotaxin, a potent chemoattractant for T cells and eosinophils. Blood 1999; 94: 2065-2071.
48. Ishida T, Ishii T, Inagaki A, Yano H, Komatsu H, Iida S, et al . Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. Cancer Res 2006; 66: 5716-5722.
49. Hopken UE, Foss HD, Meyer D, Hinz M, Leder K, Stein H, et al . Up-regulation of the chemokine receptor CCR7 in classical but not in lymphocyte-predominant Hodgkin disease correlates with distinct dissemination of neoplastic cells in lymphoid organs. Blood 2002; 99: 1109-1116.
50. Majka M, Rozmyslowicz T, Honczarenko M, Ratajczak J, Wasik MA, Gaulton GN, et al . Biological significance of the expression of HIV-related chemokine coreceptors (CCR5 and CXCR4) and their ligands by human hematopoietic cell lines. Leukemia 2000; 14: 1821-1832.
51. Van den Berg A, Visser L, Poppema S. High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltrate in Hodgkin's lymphoma. Am J Pathol 1999; 154: 1685-1691.
52. Lamprecht B, Kreher S, Anagnostopoulos I, Jöhrens K, Monteleone G, Jundt F, et al . Aberrant expression of the Th2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts Treg cells via regulation of MIP-3α. Blood 2008; 112: 3339-3347.
53. Hanamoto H, Nakayama T, Miyazato H, Takegawa S, Hieshima K, Tatsumi Y, et al . Expression of CCL28 by Reed-Sternberg cells defines a major subtype of classical Hodgkin's disease with frequent infiltration of eosinophils and/or plasma cells. Am J Pathol 2004; 164: 997-1006.
54. Renné C, Minner S, Küppers R, Hansmann ML, Bräuninger A. Autocrine NGFβ/TRKA signalling is an important survival factor for Hodgkin lymphoma derived cell lines. Leuk Res 2008; 32: 163-167. (Pubitemid 350100851)
55. Skinnider BF, Kapp U, Mak TW. The role of interleukin 13 in classical Hodgkin lymphoma. Leuk Lymphoma 2002; 43: 1203-1210. (Pubitemid 34537964)
56. Chiu A, Xu W, He B, Dillon SR, Gross JA, Sievers E, et al . Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL. Blood 2007; 109: 729-739.
57. Fiumara P, Snell V, Li Y, Mukhopadhyay A, Younes M, Gillen-water AM, et al . Functional expression of receptor activator of nuclear factor-κB in Hodgkin disease cell lines. Blood 2001; 98: 2784-2790.
58. Kato M, Sanada M, Kato I, Sato Y, Takita J, Takeuchi K, et al . Frequent inactivation of A20 in B cell lymphomas. Nature 2009; 459: 712-716.
59. Vereecke L, Beyaert R, van Loo G. The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology. Trends Immunol 2009; 30: 383-391.
60. Schmitz R, Hansmann ML, Bohle V, Martin-Subero JI, Hartmann S, Mechtersheimer G, et al . TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. J Exp Med 2009; 206: 981-989.
61. Longo CR, Arvelo MB, Patel VI, Daniel S, Mahiou J, Grey ST, et al . A20 protects from CD40-CD40 ligand-mediated endothelial cell activation and apoptosis. Circulation 2003; 108: 1113-1118. (Pubitemid 37071523)
62. Horie R, Watanabe T, Ito K, Morisita Y, Watanabe M, Ishida T, et al . Cytoplasmic aggregation of TRAF2 and TRAF5 proteins in the Hodgkin-Reed- Sternberg cells. Am J Pathol 2002; 160: 1647-1654. (Pubitemid 34525645)
63. Guo F, Sun A, Wang W, He J, Hou J, Zhou P, et al. TRAF1 is involved in the classical NF-κB activation and CD30-induced alternative activity in Hodgkin's lymphoma cells. Mol Immunol 2009; 46: 2441-2448.
64. Zheng B, Fiumara P, Li YV, Georgakis G, Snell V, Younes M, et al . MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival. Blood 2003; 102: 1019-1027. (Pubitemid 36917799)
65. Su CC, Chiu HH, Chang CC, Chen JC, Hsu SM. CD30 is involved in inhibition of T-cell proliferation by Hodgkin's Reed-Sternberg cells. Cancer Res 2004; 64: 2148-2152.
66. Casasnovas RO, Mounier N, Brice P, Divine M, Morschhauser F, Gabarre J, et al . Groupe d'Etude des Lymphomes de l'Adulte. Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: a study from the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2007; 25: 1732-1740.
67. Hsi ED. Biologic features of Hodgkin lymphoma and the development of biologic prognostic factors in Hodgkin lymphoma: tumor and microenvironment. Leuk Lymphoma 2008; 49: 1668-1680.
68. Niens M, Visser L, Nolte IM, van der Steege G, Diepstra A, Cordano P, et al . Serum chemokine levels in Hodgkin lymphoma patients: highly increased levels of CCL17 and CCL22. Br J Haematol 2008; 140: 527-536. (Pubitemid 351230079)
69. Trümper L, Jung W, Dahl G, Diehl V, Gause A, Pfreundschuh M. Interleukin-7, interleukin-8, soluble TNF receptor, and p53 protein levels are elevated in the serum of patients with Hodgkin's disease. Ann Oncol 1994; 5: 93-96. (Pubitemid 24051326)
70. Biggar RJ, Johansen JS, Smedby KE, Rostgaard K, Chang ET, Adami HO, et al . Serum YKL-40 and interleukin 6 levels in Hodgkin lymphoma. Clin Cancer Res 2008; 14: 6974-6978.
71. Gruss HJ, Hirschstein D, Wright B, Ulrich D, Caligiuri MA, Barcos M, et al . Expression and function of CD40 on Hodgkin and Reed-Sternberg cells and the possible relevance for Hodgkin's disease. Blood 1994; 84: 2305-2314. (Pubitemid 24296393)
72. Koenecke C, Ukena SN, Ganser A, Franzke A. Regulatory T cells as therapeutic target in Hodgkin's lymphoma. Expert Opin Ther Targets 2008; 12: 769-782. (Pubitemid 351877305)
73. + naive T cells. J Leukoc Biol 2007; 82: 576-584.
74. + T cells in Hodgkin lymphoma. Blood 2007; 110: 3226-3233.
75. Gandhi MK, Moll G, Smith C, Dua U, Lambley E, Ramuz O, et al . Galectin-1-mediated suppression of Epstein-Barr virus specific T-cell immunity in classic Hodgkin lymphoma. Blood 2007; 110: 1326-1329. (Pubitemid 47281432)
76. + T cell activation by inhibition of lck: implications in Hodgkin's lymphoma. Cancer Res 2006; 66: 1114-1122.
77. Poppema S, Potters M, Visser L, van den Berg AM. Immune escape mechanisms in Hodgkin's disease. Ann Oncol 1998; 9: S21-24.
78. Poppema S. Immunobiology and pathophysiology of Hodgkin lymphomas. Hematol Am Soc Hematol Educ Program 2005; 231-238.
79. Diepstra A, Poppema S, Boot M, Visser L, Nolte IM, Niens M, et al . HLA-G protein expression as a potential immune escape mechanism in classical Hodgkin's lymphoma. Tissue Antigens 2008; 71: 219-226. (Pubitemid 351197075)
80. + tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival. Hum Pathol 2009; 40: 1715-1722.
81. Brice P. Managing relapsed and refractory Hodgkin lymphoma. Br J Haematol 2008; 141: 3-13. (Pubitemid 351347529)
82. Younes A. Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma. Hematol Am Soc Hematol Educ Program 2009; 507-519.
83. Wildes TM, Bartlett NL. Drug development for recurrent and refractory classical Hodgkin lymphoma. Leuk Lymphoma 2009; 50: 529-540.
84. Gruss HJ, Pinto A, Duyster J, Poppema S, Herrmann F. Hodgkin's disease: a tumor with disturbed immunological pathways. Immunol Today 1997; 18: 156-163.
85. Alvaro T, Lejeune M, García JF, Salvadó MT, López C, Bosch R, et al . Tumor-infiltrated immune response correlates with alterations in the apoptotic and cell cycle pathways in Hodgkin and Reed-Sternberg cells. Clin Cancer Res 2008; 14: 685-691.
86. Ma Y, Visser L, Roelofsen H, de Vries M, Diepstra A, van Imhoff G, et al . Proteomics analysis of Hodgkin lymphoma: identification of new players involved in the cross-talk between HRS cells and infiltrating lymphocytes. Blood 2008; 111: 2339-2346.
87. Sánchez-Espiridión B, Sánchez-Aguilera A, Montalbán C, Martin C, Martinez R, González-Carrero J, et al. A TaqMan low-density array to predict outcome in advanced Hodgkin's lymphoma using paraffin-embedded samples. Clin Cancer Res 2009; 15: 1367-1375.
88. Terasawa T, Lau J, Bardet S, Couturier O, Hotta T, Hutchings M, et al . Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B cell lymphoma: a systematic review. J Clin Oncol 2009; 27: 1906-1914.
89. 18F-fluorodeoxyglucose positron emission tomography. Nucl Med Commun 2009; 30: 594-601.
90. 18F-FDG uptake by cells involved in pannus formation in rheumatoid arthritis. J Nucl Med 2009; 50: 920-926.
91. Poppema S. Immunology of Hodgkin's disease. Baillière's Clin Haematol 1996; 9: 447-457.
92. Gruss HJ, Pinto A, Gloghini A, Wehnes E, Wright B, Boiani N, et al . CD30 ligand expression in nonmalignant and Hodgkin's disease-involved lymphoid tissues. Am J Pathol 1996; 149: 469-481.
93. - T-cell population in classical Hodgkin's lymphoma displays a distinctive regulatory T-cell profile. Lab Invest 2008; 88: 482-490.
94. de Jong D, Enblad G. Inflammatory cells and immune microenvironment in malignant lymphoma. J Int Med 2008; 264: 528-536.
95. Carbone A, Gloghini A, Serraino D, Spina M. HIV-associated Hodgkin lymphoma. Curr Opin HIV AIDS 2009; 4: 3-10.
96. Rodig SJ, Abramson JS, Pinkus GS, Treon SP, Dorfman DM, Dong HY, et al . Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H). Clin Cancer Res 2006; 12: 7174-7179.
97. Peggs KS, Sureda A, Qian W, Caballero D, Hunter A, Urbano- Ispizua A, et al . Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes. Br J Haematol 2007; 139: 70-80.
98. Thomson KJ, Peggs KS, Smith P, Cavet J, Hunter A, Parker A, et al . Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation. Bone Marrow Transpl 2008; 41: 765-770.
99. Braiteh F, Ng C, Kurzrock R. Refractory Hodgkin lymphoma responds to pentostatin (2′-deoxycoformycin). Leuk Lymphoma 2006; 47: 373-375.
100. -/- colitis. Inflamm Bowel Dis 2008; 14: 880-887.
101. Aldinucci D, Poletto D, Lorenzon D, Nanni P, Degan M, Olivo K, et al . CD26 expression correlates with a reduced sensitivity to 2′- deoxycoformycin-induced growth inhibition and apoptosis in T-cell leukemia/lymphomas. Clin Cancer Res 2004; 10: 508-520.
102. Oki Y, Younes A. Current role of gemcitabine in the treatment of Hodgkin lymphoma. Leuk Lymphoma 2008; 49: 883-889.
103. Correale P, Tagliaferri P, Fioravanti A, Del Vecchio MT, Remondo C, Montagnani F, et al . Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine + FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 trial). Clin Cancer Res 2008; 14: 4192-4199.
104. Rassidakis GZ, Medeiros LJ, Viviani S, Bonfante V, Nadali GP, Vassilakopoulos TP, et al . CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's disease: associations with presenting features and clinical outcome. J Clin Oncol 2002; 20: 1278-1287.
105. Clodi K, Asgari Z, Younes M, Palmer JL, Cabanillas F, Carbone A, et al . Expression of CD40 ligand (CD154) in B and T lymphocytes of Hodgkin disease: potential therapeutic significance. Cancer 2002; 94: 1-5.
106. Chetaille B, Bertucci F, Finetti P, Esterni B, Stamatoullas A, Picquenot JM, et al . Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome. Blood 2009; 113: 2765-3775.
107. Younes A, Zhao S, Zhang X, Snell V, Clodi K, Kliche KO, et al . CD30-ligand and CD40-ligand expression in lymph nodes involved with Hodgkin's disease. Ann Oncol 1997; 8: 97-100.
108. Gattei V, Degan M, Gloghini A, De Iuliis A, Improta S, Rossi FM, et al . CD30 ligand is frequently expressed in human hematopoietic malignancies of myeloid and lymphoid origin. Blood 1997; 89: 2048-2059.
109. Jones RJ, Gocke CD, Kasamon YL, Miller CB, Perkins B, Barber JP, et al . Circulating clonotypic B cells in classic Hodgkin lymphoma. Blood 2009; 113: 5920-5926.
110. De Filippi R, Russo F, Iaccarino G, Crisci S, Frigeri F, Riemma C, et al . Abnormally elevated levels of serum-free immunoglobulin light chains are frequently found in classic Hodgkin lymphoma (cHL) and predict outcome of patients with early stage disease. Blood: ASH Annu Meet Abstr 2009; 114: 267.
111. Enblad G, Molin D, Glimelius I, Fischer M, Nilsson G. The potential role of innate immunity in the pathogenesis of Hodgkin's lymphoma. Hematol Oncol Clin North Am 2007; 21: 805-823.
112. Younes A, Romaguera J, Hagemeister F, McLaughlin P, Rodriguez MA, Fiumara P, et al . A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer 2003; 98: 310-314.
113. Oki Y, Pro B, Fayad LE, Romaguera J, Samaniego F, Hagemeister F, et al . Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma. Cancer 2008; 112: 831-836.
114. Corazzelli G. J Clin Oncol 2008 ASCO Annual Meeting Proceedings 2008; 26: 8532 [Abstr].
115. Wedgwood AR, Fanale MA, Fayad LE, McLaughlin P, Hagemeister FB, Pro B, et al . Rituximab ABVD improves event-free survival (EFS) in patients with classical Hodgkin lymphoma in all international prognostic score (IPS) groups and in patients who have PET-positive disease after 2-3 cycles of therapy. ASH Annu Meet Abstr 2007; 110: 215.
116. HD18 for advanced stages in Hodgkins lymphoma. NCT00515554: http://clinicaltrials.gov [accessed 10 January 2009].
117. Younes A, Wong F. Experience with 90Y-ibritumomab tiuxetan for relapsed classical Hodgkin lymphoma. Ann Oncol 2009; 20: 1147-1148.
118. Safety and efficacy study of I-131 tositumomab in patients with relapsed/refractory Hodgkin's lymphoma. NCT00484874: http://clinicaltrials.gov [accessed 10 January 2009].
119. Ambrose LR, Morel AS, Warrens AN. Neutrophils express CD52 and exhibit complement-mediated lysis in the presence of alemtuzumab. Blood 2009; 114: 3052-3055.
120. Zhang PL, Pennington JR, Prichard JW, Blasick TM, Brown AM, Potdar S. CD52 antigen may be a therapeutic target for eosinophilic rhinosinusitis. Ann Clin Lab Sci 2007; 37: 148-151.
121. Santos DD, Hatjiharissi E, Tournilhac O, Chemaly MZ, Leleu X, Xu L, et al . CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's macroglobulinemia and mast cell disorders. Clin Lymphoma Myeloma 2006; 6: 478-483.
122. Verstovsek S, Tefferi A, Kantarjian H, Manshouri T, Luthra R, Pardanani A, et al . Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia. Clin Cancer Res 2009; 15: 368-373.
123. Pinto A, Aldinucci D, Gloghini A, Zagonel V, Degan M, Improta S, et al . Human eosinophils express functional CD30 ligand and stimulate proliferation of a Hodgkin's disease cell line. Blood 1996; 88: 3299-3305.
124. Raab M S, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Multiple myeloma. Lancet 2009; 374: 324-339.
125. Chanan-Khan AA, Cheson BD. Lenalidomide for the treatment of B cell malignancies. J Clin Oncol 2008; 26: 1544-1552.
126. Böll B, Borchmann P, Topp MS, Hänel M, Reiners KS, Engert A, Naumann R. Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma. Br J Haematol 2010; 148: 480-482.
127. Corazzelli G, De Filippi R, Capobianco G, Frigeri F, De Rosa V, Iaccarino G, et al . Tumor flare reactions and response to lenalidomide in patients with refractory classic Hodgkin lymphoma. Am J Hematol 2010; 85: 87-90.
128. Kuruvilla J, Taylor D, Wang L, Blattler C, Keating A, Crump M. Phase II trial of lenalidomide in patients with relapsed or refractory Hodgkin lymphoma [abstr]. Blood: ASH Annu Meet Abstr 2008; 112: 3052.
129. Fehniger TA, Larson S, Trinkaus K, Siegel MJ, Cashen AF, Blum A K, et al . A phase II multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood: ASH Annu Meet Abstr 2009; 114: 3693.
130. Wallentine JC, Kim KK, Seiler CE 3rd, Vaughn CP, Crockett DK, Tripp SR, et al . Comprehensive identification of proteins in Hodgkin lymphoma-derived Reed-Sternberg cells by LC-MS/MS. Lab Invest 2007; 87: 1113-1124.
131. Sauer S, Erba PA, Petrini M, Menrad A, Giovannoni L, Grana C, et al . Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients. Blood 2009; 113: 2265-2274.
132. Schliemann C, Wiedmer A, Pedretti M, Szczepanowski M, Klapper W, Neri D. Three clinical-stage tumor targeting antibodies reveal differential expression of oncofetal fibronectin and tenascin-C isoforms in human lymphoma. Leuk Res 2009; 33: 1718-1722.
133. 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma. Blood 2004; 104: 642-648.
134. Di Stasi A, De Angelis B, Rooney CM, et al . T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumour activity in a Hodgkin tumour model. Blood 2009; 113: 6392-6402.
135. Vaday GG, Peehl DM, Kadam PA, Lawrence DM. Expression of CCL5 (RANTES) and CCR5 in prostate cancer. Prostate 2006; 66: 124-134.
136. Murooka TT, Rahbar R, Fish EN. CCL5 promotes proliferation of MCF-7 cells through mTOR-dependent mRNA translation. Biochem Biophys Res Commun 2009; 387: 381-386.
137. Levina V, Su Y, Nolen B, Liu X, Gordin Y, Lee M, et al . Chemotherapeutic drugs and human tumour cells cytokine network. Int J Cancer 2008; 123: 2031-2040.